DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

DBV Technologies announced its participation in the H.C. Wainwright Global Life Sciences Conference taking place on March 9-10, 2021. CEO Daniel Tassé will present during the event. A webcast of the presentation will be available on the company’s website starting March 9 at 7:00 a.m. ET. DBV Technologies focuses on developing Viaskin™, a proprietary platform for epicutaneous immunotherapy, targeting food allergies, with ongoing trials for Viaskin Peanut. The company is headquartered in Montrouge, France, and trades on Euronext Paris (DBV) and Nasdaq (DBVT).

News Market Reaction – DBVT

+0.77%

1 alert

+0.77% News Effect

On the day this news was published, DBVT gained 0.77%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Montrouge, France, March 5, 2021

DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held March 9-10, 2021.

A webcast of the presentation at the H.C. Wainwright Healthcare Conference will be available on the Investors & Media section of the Company’s website beginning Tuesday, March 9^th at 7:00 a.m. ET: https://www.dbv-technologies.com/investor-relations/.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com

 

Attachment

• PDF Version

FAQ

When is DBV Technologies presenting at the H.C. Wainwright Global Life Sciences Conference?

DBV Technologies will present on March 9-10, 2021.

Who will represent DBV Technologies at the H.C. Wainwright Conference?

CEO Daniel Tassé will represent DBV Technologies at the conference.

Where can I watch DBV Technologies' conference presentation?

The presentation will be available as a webcast on DBV Technologies' website starting March 9 at 7:00 a.m. ET.

What technology is DBV Technologies developing?

DBV Technologies is developing Viaskin™, a platform for epicutaneous immunotherapy aimed at treating food allergies.

What ongoing clinical trials is DBV Technologies conducting?

DBV Technologies is conducting ongoing clinical trials for Viaskin Peanut.